A 55-year-old male patient with myelodysplastic syndrome undergoes regular red cell transfusions due to symptomatic anemia. When his serum ferritin rises above 1000 ng/mL, which chelation therapy is most appropriate to initiate?
সমাধান
সঠিক উত্তর: Option D
When managing iron overload in patients with myelodysplastic syndrome (MDS) who receive regular red blood cell transfusions, it is crucial to begin iron chelation therapy once serum ferritin levels consistently exceed 1000 ng/mL. This threshold indicates significant iron accumulation, which can lead to organ damage if left untreated.
- Iron overload is a common complication in transfusion-dependent MDS, resulting from excess iron in the body due to repeated transfusions.
- The primary goal of chelation therapy is to reduce the total body iron burden and prevent complications such as cardiac, hepatic, and endocrine dysfunction.
- Three main iron chelators are available: Deferasirox, Deferoxamine, and Deferiprone.
- Each chelator has its own route of administration, side effect profile, and patient compliance considerations:
- Deferasirox: Oral once-daily dosing, convenient but may cause renal or hepatic toxicity.
- Deferoxamine: Parenteral (subcutaneous or intravenous), less convenient, but widely used historically.
- Deferiprone: Oral, but associated with risks like agranulocytosis and requires regular blood count monitoring.
Important Points:
- The choice of agent should be individualized based on patient-specific factors, including tolerance, comorbidities, route of administration preference, risk of adverse effects, and patient compliance.
- No single chelator is universally superior; therefore, any of the three chelators can be appropriate when tailored to the patient's clinical context.
- Regular monitoring of serum ferritin, organ function, and adverse effects is essential regardless of the chosen therapy.
In summary, initiation of iron chelation in MDS patients with serum ferritin > 1000 ng/mL is indicated, and the most appropriate chelator depends on patient-specific factors and shared decision-making, making all three options viable.
Reference: Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB. *Postgraduate Haematology*, 7th Edition, Volume 1, Chapter 27: Iron Overload and its Management, pp. 351-368.
- Iron overload is a common complication in transfusion-dependent MDS, resulting from excess iron in the body due to repeated transfusions.
- The primary goal of chelation therapy is to reduce the total body iron burden and prevent complications such as cardiac, hepatic, and endocrine dysfunction.
- Three main iron chelators are available: Deferasirox, Deferoxamine, and Deferiprone.
- Each chelator has its own route of administration, side effect profile, and patient compliance considerations:
- Deferasirox: Oral once-daily dosing, convenient but may cause renal or hepatic toxicity.
- Deferoxamine: Parenteral (subcutaneous or intravenous), less convenient, but widely used historically.
- Deferiprone: Oral, but associated with risks like agranulocytosis and requires regular blood count monitoring.
Important Points:
- The choice of agent should be individualized based on patient-specific factors, including tolerance, comorbidities, route of administration preference, risk of adverse effects, and patient compliance.
- No single chelator is universally superior; therefore, any of the three chelators can be appropriate when tailored to the patient's clinical context.
- Regular monitoring of serum ferritin, organ function, and adverse effects is essential regardless of the chosen therapy.
In summary, initiation of iron chelation in MDS patients with serum ferritin > 1000 ng/mL is indicated, and the most appropriate chelator depends on patient-specific factors and shared decision-making, making all three options viable.
Reference: Hoffbrand AV, Higgs DR, Keeling DM, Mehta AB. *Postgraduate Haematology*, 7th Edition, Volume 1, Chapter 27: Iron Overload and its Management, pp. 351-368.